Evidence map›Paper›PMID 41888038›Full record

Trial reportBritish journal of haematology2026

MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM.

Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti and 15 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Alessandro GozzettiDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Paola PacelliDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.ORCID https://orcid.org/0000-0001-5838-1123
Federico CaroniDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Donatella RaspadoriDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Elena BestosoDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Elisabetta AntonioliDepartment of Hematology, Careggi Hospital and University of Florence, Florence, Italy.
Gabriele BudaDepartment of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy.
Sara CiofiniDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Adele SantoniDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Luca PuccettiDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.ORCID https://orcid.org/0000-0002-4022-8822
Francesca BacchiarriDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.ORCID https://orcid.org/0000-0001-6186-3895
Ludovica PengueDepartment of Hematology, Careggi Hospital and University of Florence, Florence, Italy.
Dania TocciDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Irene AttucciDepartment of Hematology, Careggi Hospital and University of Florence, Florence, Italy.
Maria Livia Del GiudiceDepartment of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy.
Miriana RuggieriDepartment of Hematology and Stem Cell Transplantation Unit, C. E G. Mazzoni Hospital, Ascoli Piceno, Italy.
Alessandra LombardoHem/Onc Unit, Azienda Ospedaliera Santa Maria Terni, Terni, Italy.
Anna Marina LiberatiUniversity of Perugia, Perugia, Italy.
Veronica CandiHematology Unit, San Donato Hospital, Arezzo, Italy.
Vincenzo SammartanoDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.
Alessandra CartocciDepartment of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Anna SicuranzaDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.ORCID https://orcid.org/0000-0002-5840-2956
Sara GalimbertiDepartment of Clinical and Experimental Medicine, Hematology, University of Pisa, Pisa, Italy.
Alessandro Maria VannucchiDepartment of Hematology, Careggi Hospital and University of Florence, Florence, Italy.
Monica BocchiaDepartment of Medicine, Surgery and Neuroscience, Hematology, University of Siena, Siena, Italy.

Funding

Janssen Research and Development
6 · The paper itself

Abstract

Daratumumab is approved for front-line and relapsed myeloma therapy. Here, we evaluated daratumumab in multiple myeloma patients already in ≥very good partial response but minimal residual disease (MRD) positive by next-generation flow after first-line therapy and daratumumab naïve with the potential to eradicate the disease. In this prospective, single-arm phase 2 trial, we consecutively evaluated 110 eligible patients with newly diagnosed multiple myeloma for positivity at 10

Indexed as

Antibodies, MonoclonalAntineoplastic AgentsMultiple MyelomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm, ResidualProspective StudiesAntibodies, MonoclonalAntineoplastic Agentsdaratumumabconsolidation therapydaratumumabMRDmultiple myeloma

Identifiers

PMID41888038
PMCPMC13267446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.